In vivo PET imaging with [18F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes

No Thumbnail Available
Journal Title
Journal ISSN
Volume Title
Springer Nature
Type 2 diabetes is characterised by decreased HDL levels, as well as the level of apolipoprotein A-I (apoA-I), the main apolipoprotein of HDLs. Pharmacological elevation of HDL and apoA-I levels is associated with improved glycaemic control in patients with type 2 diabetes. This is partly due to improved glucose uptake in skeletal muscle.© 2016 Springer Nature
Diabetes mellitus, Fluorodeoxyglucose, Insulin, Kinetics, Positron computed tomography, Simulation, Lipoproteins, Radiopharmaceuticals, Phosphorylation
Cochran, B. J., Ryder, W. J., Parmar, A., Tang, S., Reilhac, A., Arthur, A., Charil, A., Hamze, H., Barter, P. J., Kritharides, L. Meikle, S. R., Grégoire, M. C. & Rye, K. (2016). In vivo PET imaging with [18F] FDG to explain improved glucose uptake in an apolipoprotein AI treated mouse model of diabetes. Diabetologia, 59(9), 1977-1984. doi:10.1007/s00125-016-3993-5